Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy
Patil PA, Zhang X. Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. Archives Of Pathology & Laboratory Medicine 2020, 145: 571-582. PMID: 32338534, DOI: 10.5858/arpa.2020-0070-ra.Peer-Reviewed Original ResearchMeSH KeywordsDiagnosis, DifferentialDigestive SystemDigestive System DiseasesHumansImmune Checkpoint InhibitorsInflammationConceptsHepatobiliary injuryCheckpoint inhibitorsCPI therapyActive colitisPathologic manifestationsCytotoxic T-lymphocyte-associated protein 4 inhibitorsT-lymphocyte-associated protein 4 inhibitorsImmune checkpoint inhibitor therapyDeath ligand 1 (PD-L1) inhibitorsAdverse effectsChronic active colitisAdministration of steroidsCheckpoint inhibitor therapyDeath receptor-1Immune checkpoint inhibitorsBile duct injuryChronic active gastritisLigand 1 inhibitorsNodular regenerative hyperplasiaSecondary sclerosing cholangitisDifferential diagnostic considerationsProtein 4 inhibitorsSeverity of injuryIschemic colitisPanlobular hepatitis